NEW YORK, May 4, 2017 /PRNewswire/ --
Stock-Callers.com has initiated research reports on these four stocks: VWRCorp. (NASDAQ: VWR), Bruker Corp. (NASDAQ: BRKR), PerkinElmer Inc. (NYSE: PKI), and Charles River Laboratories International Inc. (NYSE: CRL). Companies in the Medical Laboratories and Research industry are focused on performing various tests on patients
On Wednesday, shares in Radnor, Pennsylvania-based VWR Corp. recorded a trading volume of 11.64 million shares, which was above their three months average volume of 705,860 shares. The stock ended at $33.62, surging 17.88% from the last trading session. The Company's shares have gained 19.05% in the last one month, 26.92% over the previous three months, and 34.32% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 21.03% and 22.84%, respectively. Furthermore, shares of VWR, which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have a Relative Strength Index (RSI) of 89.82.
On April 27th, 2017, The VWR Foundation, a charitable organization established by a group of associates from VWR Corp., announced that it distributed six grants totaling over $44,000 during its Board Meeting earlier in April. Five of the grants were awarded to organizations that are new to the VWR Foundation, and all of them support science education programs. Access our complete research report on VWR for free at:
Billerica, Massachusetts headquartered Bruker Corp.'s stock finished yesterday's session 1.63% higher at $24.91. A total volume of 987,152 shares was traded, which was above their three months average volume of 692,230 shares. The Company's shares have gained 6.77% in the last one month, 4.44% over the previous three months, and 17.80% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.84% and 9.99%, respectively. Furthermore, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 73.85.
On April 27th, 2017, Bruker announced that it will present at the 42nd annual Deutsche Bank Health Care Conference at The InterContinental Hotel, 510 Atlantic Avenue, Boston. Frank Laukien, Chairman, President, and CEO will participate in a "fireside chat" Q&A session on behalf of the Company on Thursday, May 04th, 2017 at 8:40 a.m. ET. A live, audio webcast of the presentation will be available under the Investor section of the Company's website. The complimentary research report on BRKR can be downloaded at:
At the close of trading on Wednesday, shares in Waltham, Massachusetts headquartered PerkinElmer Inc. ended the day flat at $59.64. The stock recorded a trading volume of 456,667 shares. The Company's shares have advanced 2.95% in the last one month, 11.07% in the previous three months, and 14.65% since the start of this year. The stock is trading 4.82% and 10.22% above its 50-day and 200-day moving averages, respectively. Moreover, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have an RSI of 67.68.
On May 01st, 2017, PerkinElmer announced that it has completed the sale of its Medical Imaging business to Varex Imaging Corporation. The former announced its intent to sell its Medical Imaging business - a supplier of flat panel X-ray detectors that serve as components for industrial, medical and dental X-ray imaging systems - on December 22nd, 2016. Register for free on Stock-Callers.com and get access to the latest PDF format report on PKI at:
Charles River Laboratories
Wilmington, Massachusetts headquartered Charles River Laboratories International Inc.'s shares ended the day 0.37% lower at $90.03 with a total trading volume of 238,890 shares. The stock has gained 0.63% in the last month, 9.90% over the previous three months, and 18.17% on an YTD basis. The Company's shares are trading 1.60% above their 50-day moving average and 9.62% above their 200-day moving average. Additionally, shares of Charles River Labs, which provides drug discovery and development services worldwide, have an RSI of 59.75.
On April 12th, 2017, Charles River Labs announced that it will release Q1 2017 financial results on Wednesday, May 10th, 2017, before the market opens. A conference call has been scheduled to discuss this information on that same day at 8:30 a.m. ET. The live webcast of the conference call can be accessed under the Investor Relations section of the Company's website. Download your free research report on CRL at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All